Indications and Usage

Wegovy™ (semaglutide) injection 2.4 mg is indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of ≥30 kg/m² (obesity) or ≥27 kg/m² (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia).

Limitations of Use

• Wegovy™ contains semaglutide and should not be coadministered with other semaglutide-containing products or with any GLP-1 receptor agonist.
• The safety and effectiveness of Wegovy™ in combination with other products intended for weight loss, including prescription drugs, over-the-counter drugs, and herbal preparations, have not been established.
• Wegovy™ has not been studied in patients with a history of pancreatitis.

Important Safety Information

WARNING: RISK OF THYROID C-CELL TUMORS

• In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether Wegovy™ causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined.
• Wegovy™ is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk for MTC with the use of Wegovy™ and inform them of symptoms of thyroid tumors (e.g. a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with Wegovy™.
**Introducing the Wegovy™ pen**

Once-weekly dosing with a single-dose, pre-filled pen

- Pen-injector with an integrated needle
- Allows patients to administer a preset dose

For more information about Wegovy™, visit WegovyPro.com

**How to administer Wegovy™**

- Once-weekly, on the same day each week, at any time of day
- The time of day and the injection site can be changed without dose adjustment
- With or without meals
- Subcutaneously in the abdomen, thigh, or upper arm
- Only administer if solution is clear, colorless, and contains no particles

**Important Safety Information (cont’d)**

**Contraindications**
- Wegovy™ is contraindicated in patients with a personal or family history of MTC or in patients with MEN 2, and in patients with a prior serious hypersensitivity reaction to semaglutide or to any of the excipients in Wegovy™. Serious hypersensitivity reactions, including anaphylaxis and angioedema have been reported with semaglutide.

**Warnings and Precautions**

- **Risk of Thyroid C-Cell Tumors:** Patients should be further evaluated if serum calcitonin is measured and found to be elevated or thyroid nodules are noted on physical examination or neck imaging.
- **Acute Pancreatitis:** Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with GLP-1 receptor agonists, including semaglutide. Acute pancreatitis was observed in patients treated with Wegovy™ in clinical trials. Observe patients carefully for signs and symptoms of acute pancreatitis (including persistent severe abdominal pain, sometimes radiating to the back, and which may or may not be accompanied by vomiting). If acute pancreatitis is suspected, discontinue Wegovy™ promptly, and if acute pancreatitis is confirmed, do not restart.

Please see additional Important Safety Information throughout. Please click here for Prescribing Information, including Boxed Warning, for Wegovy™.
The Wegovy™ pen contains 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, or 2.4 mg semaglutide

Each Wegovy™ pen is a different color to help identify the different dose strengths.

Dose-escalation schedule

Escalate the Wegovy™ dose up every 4 weeks for 16 weeks

- **Weeks 1-4**: 0.25 mg for 4 weeks
- **Weeks 5-8**: 0.5 mg for 4 weeks
- **Weeks 9-12**: 1 mg for 4 weeks
- **Weeks 13-16**: 1.7 mg for 4 weeks
- **Week 17 and onward**: 2.4 mg maintenance dose

Follow the dose-escalation schedule to minimize gastrointestinal adverse reactions

• In patients with type 2 diabetes, monitor blood and glucose prior to starting Wegovy™ and during Wegovy™ treatment.

Important Safety Information (cont’d)

**Warnings and Precautions (cont’d)**

- **Acute Kidney Injury**: There have been postmarketing reports of acute kidney injury and worsening of chronic renal failure, which in some cases required hemodialysis, in patients treated with semaglutide. Patients with renal impairment may be at a greater risk of acute kidney injury, but some events have been reported in patients without known underlying renal disease. A majority of the events occurred in patients who experienced nausea, vomiting, or diarrhea, leading to volume depletion. Monitor renal function when initiating or escalating doses of Wegovy™ in patients reporting severe adverse gastrointestinal reactions and in patients with renal impairment reporting any adverse reactions that could lead to volume depletion.

What to do if...

Patients need additional time to adjust to Wegovy™

• If patients do not tolerate a dose during dose escalation, consider delaying dose escalation for 4 weeks
• If patients do not tolerate the maintenance 2.4 mg dose
  — The dose can be temporarily decreased to 1.7 mg weekly, for a maximum of 4 weeks
  — After 4 weeks, increase Wegovy™ to the maintenance 2.4 mg once-weekly
  — Discontinue Wegovy™ if the patient cannot tolerate the 2.4 mg dose

Patients miss 1 dose and the next dose is:

• >2 days away (48 hours): instruct them to administer Wegovy™ as soon as possible
• <2 days away (48 hours): inform them to NOT administer a dose of Wegovy™
  — Resume dosing on the regularly scheduled day of the week

Patients miss more than 2 consecutive doses:

• Inform them to resume dosing as scheduled, or
• If needed, inform them to reinitiate Wegovy™ and follow the dose-escalation schedule, which may reduce the occurrence of GI symptoms associated with reinitiation of treatment

GI, gastrointestinal.

Encourage your patients to check in throughout their dose-escalation schedule to assess progress and tolerability

Please see additional Important Safety Information throughout. Please [click here](#) for Prescribing Information, including Boxed Warning, for Wegovy™.
What to know about prescribing Wegovy™

- A new prescription is required for each dose strength
- No separate Rx or co-pay for needles as each pen has an integrated needle
- For patients who receive a starter kit, which includes a 1-month supply of four 0.25 mg Wegovy™ pens, record it in the EHR by checking the “samples given” box
  - Write prescription for 0.5 mg
  - Encourage your patients to check in throughout their dose-escalation schedule to assess progress and tolerability
- After your patients reach the 2.4 mg maintenance dose, you can consider a 3-month Rx

EHR, electronic health record.

Important Safety Information (cont’d)

Warnings and Precautions (cont’d)

- **Hypersensitivity:** Serious hypersensitivity reactions (e.g., anaphylaxis, angioedema) have been reported with semaglutide. If hypersensitivity reactions occur, discontinue use of Wegovy™, treat promptly per standard of care, and monitor until signs and symptoms resolve. Use caution in a patient with a history of anaphylaxis or angioedema with another GLP-1 receptor agonist.

Please see additional Important Safety Information throughout. Please [click here](#) for Prescribing Information, including Boxed Warning, for Wegovy™.

How to prescribe once-weekly Wegovy™

Wegovy™ comes in 5 packs (one for each strength). Each pack contains 4 Wegovy™ pens (one pen for each week).

<table>
<thead>
<tr>
<th>Strength</th>
<th>NDC</th>
<th>Days Supply</th>
<th>Dispense Quantity</th>
<th>Recommended SIG</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.25 mg/0.5 mL</td>
<td>0169-4525-14</td>
<td>28 days</td>
<td>2 mL (mL only)</td>
<td>Inject 0.25 mg SC once weekly for 4 weeks (28 days)</td>
</tr>
<tr>
<td>0.5 mg/0.5 mL</td>
<td>0169-4505-14</td>
<td>28 days</td>
<td>2 mL (mL only)</td>
<td>Inject 0.5 mg SC once weekly for 4 weeks (28 days)</td>
</tr>
<tr>
<td>1 mg/0.5 mL</td>
<td>0169-4501-14</td>
<td>28 days</td>
<td>2 mL (mL only)</td>
<td>Inject 1 mg SC once weekly for 4 weeks (28 days)</td>
</tr>
<tr>
<td>1.7 mg/0.75 mL</td>
<td>0169-4517-14</td>
<td>28 days</td>
<td>3 mL (mL only)</td>
<td>Inject 1.7 mg SC once weekly for 4 weeks (28 days)</td>
</tr>
<tr>
<td>2.4 mg/0.75 mL</td>
<td>0169-4524-14</td>
<td>84 days*</td>
<td>9 mL* (mL only)</td>
<td>Inject 2.4 mg SC once weekly for 12 weeks (84 days*)</td>
</tr>
</tbody>
</table>

**Dispense as written**

Check the “dispense as written” (DAW) box

**Note to pharmacy**

Please dispense brand name Wegovy™, not to be confused with other semaglutide-containing products

NDC, National Drug Code; SC, subcutaneous.
*A 3-month supply for appropriate patients would be dispensed as 3 packs, each containing 4 Wegovy™ 2.4 mg dose single-use pens (2.4 mg/0.75 mL) for a total dispense quantity of 9 mL.*
Tell your patients to keep Wegovy™ pens in the refrigerator

<table>
<thead>
<tr>
<th>Storage and Handling for Wegovy™</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Store Wegovy™ pen in refrigerator from 36°F to 46°F (2°C to 8°C)</td>
</tr>
<tr>
<td>• If needed, prior to cap removal, Wegovy™ pens can be kept from 46°F to 86°F (8°C to 30°C) up to 28 days</td>
</tr>
</tbody>
</table>

• Do not freeze
• Protect Wegovy™ from light
• Wegovy™ must be kept in the original carton until time of administration
• Discard the Wegovy™ pen after use

Important Safety Information (cont’d)

Warnings and Precautions (cont’d)

• Diabetic Retinopathy Complications in Patients with Type 2 Diabetes: In a trial of patients with type 2 diabetes, diabetic retinopathy was reported by 4.0% of Wegovy™ patients and 2.7% of placebo patients. Rapid improvement in glucose control has been associated with a temporary worsening of diabetic retinopathy. Patients with a history of diabetic retinopathy should be monitored for progression of diabetic retinopathy.
• Heart Rate Increase: Mean increases in resting heart rate of 1 to 4 beats per minute (bpm) were observed in Wegovy™ patients compared to placebo in clinical trials. More Wegovy™ patients compared with placebo had maximum changes from baseline of 10 to 19 bpm (41% versus 34%) and 20 bpm or more (26% versus 16%). Monitor heart rate at regular intervals and instruct patients to report palpitations or feelings of a racing heartbeat while at rest. If patients experience a sustained increase in resting heart rate, discontinue Wegovy™.

Important Safety Information (cont’d)

Warnings and Precautions (cont’d)

• Suicidal Behavior and Ideation: Suicidal behavior and ideation have been reported in clinical trials with other weight management products. Monitor patients for depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior. Discontinue Wegovy™ in patients who experience suicidal thoughts or behaviors and avoid in patients with a history of suicidal attempts or active suicidal ideation.

Adverse Reactions
• The most common adverse reactions reported in ≥5% of patients treated with Wegovy™ are nausea, diarrhea, vomiting, constipation, abdominal pain, headache, fatigue, dyspepsia, dizziness, abdominal distention, eructation, hypoglycemia in patients with type 2 diabetes, flatulence, gastroenteritis, and gastroesophageal reflux disease.

Drug Interactions
• The addition of Wegovy™ in patients treated with insulin has not been evaluated. When initiating Wegovy™, consider reducing the dose of concomitantly administered insulin secretagogues (such as sulfonylureas) or insulin to reduce the risk of hypoglycemia.
• Wegovy™ causes a delay of gastric emptying and has the potential to impact the absorption of concomitantly administered oral medications. Monitor the effects of oral medications concomitantly administered with Wegovy™.

Use in Specific Populations
• Pregnancy: May cause fetal harm. When pregnancy is recognized, discontinue Wegovy™. Discontinue Wegovy™ in patients at least 2 months before a planned pregnancy.
Check your patient’s coverage and savings eligibility at WegovyCoverage.com:
Your patients with Saxenda® (liraglutide) injection 3 mg coverage may be eligible for a special Wegovy™ savings offer

1. Verify pharmacy benefits in minutes
2. Once verified, prescribe Wegovy™ and provide a patient starter kit
3. Fax the completed Wegovy™ savings request form to the NovoCare® Live Hub and provide patients with savings offer information

Eligible* patients will pay $25 per 28-day prescription for up to 6 fills

*Eligibility and restrictions apply. For six 28-day fills for eligible commercially insured patients with coverage for branded anti-obesity medications, whose coverage is confirmed via a benefits verification. Novo Nordisk reserves the right to modify or cancel this program at any time. See terms and conditions at wegovyterms2021.com.

WeGoTogether™
Give your patients personalized support
This program helps your patients get started and stay on track with Wegovy™. It includes behavior modification tools and gives patients access to:

- Savings options for Wegovy™
- Choice of live phone coaching or text/email-based coaching (same Coach throughout the program)
- Direct access to a Health Coach who provides:
  - Tips to help patients stay on track
  - Assistance with using the Wegovy™ pen
  - Support to help your patients manage their weight
  - Motivation to make lifestyle changes
- A personalized web portal where patients can track or log their weekly dose, set goals, and share their weight progress with their Coach

Please see additional Important Safety Information throughout.
Please click here for Prescribing Information, including Boxed Warning, for Wegovy™.
Please click here for Prescribing Information, including Boxed Warning, for Saxenda®.


Wegovy™ and WeGoTogether™ are trademarks of Novo Nordisk A/S.
NovoCare® and Saxenda® are registered trademarks of Novo Nordisk A/S.
Novo Nordisk is a registered trademark of Novo Nordisk A/S. All other trademarks, registered or unregistered, are property of their respective owners.
© 2021 Novo Nordisk  Printed in the U.S.A.  US21SEMO00358  June 2021